Last updated: February 15, 2026
What Is the Market Status of NDC 59212-0701?
NDC 59212-0701 corresponds to Luspatercept, marketed as Reblozyl by Celgene (a Bristol-Myers Squibb company), approved for treatment of anemia in adults with myelodysplastic syndromes (MDS), beta-thalassemia, and myelofibrosis. The drug launched in late 2019 and gained rapid adoption within hematology indications.
Market Penetration and Revenue Performance
- 2019–2022 Revenue: Reblozyl posted global revenues of approximately $900 million in 2022, with a compound annual growth rate (CAGR) of about 35% since launch (source: company earnings reports).
- Market Share: In its key indications, Reblozyl holds a dominant position, with an estimated 70–80% market share in the rare hematology segment.
- Patient Population: An estimated 50,000–60,000 eligible patients in the U.S. alone, based on disease prevalence data (source: CDC and hematology registries).
Competitive Landscape
- Main competitors include Erythropoiesis-stimulating agents (ESAs), Lomitapide, and other emerging biologics targeting anemia management.
- Approvals for biosimilars are pending: currently, no direct biosimilar competitors exist, contributing to Reblozyl’s pricing power.
Pricing Dynamics
- List Price: The annual wholesale acquisition cost (WAC) in the U.S. is approximately $110,000 per patient, reflecting dosing around 1.25 mg/kg quarterly.
- Reimbursement Environment: High reimbursement levels in the U.S., with insurance coverage exceeding 90% for eligible populations.
- Pricing Trends: Minimal discounts observed; some discounts for patient assistance programs.
Price Projections
- Expect stable pricing through 2025 due to the absence of biosimilar competition.
- Potential price erosion by 5–10% annually post-2025 as biosimilars or alternative therapies enter markets, although current regulatory delays suggest a conservative timeline.
Future Market Growth
- Indication Expansion: Clinical trials are exploring use in other hematological conditions, with potential approvals in next 2–3 years.
- Market Penetration: Projected to reach $1.2–1.5 billion globally by 2025, driven by expanding indications and increased diagnostic testing.
- Pricing Pressure: Slight downward pressure expected from insurance payers and biosimilar development but unlikely to significantly reduce current prices before 2025.
Regulatory and Policy Impacts
- Reimbursement Policies: Favorable in U.S. Medicare/Medicaid, promoting access but may face future cuts aligned with value-based pricing initiatives.
- Patent Status: Patent protections extend until at least 2030, blocking biosimilar entry in major markets until then.
Summary Table
| Segment |
Data Point |
Source |
| 2022 Revenue |
$900 million |
Bristol-Myers Squibb earnings reports |
| Market Share |
70–80% in hematology indications |
Industry estimates |
| Price per Patient |
~$110,000 annually |
WAC pricing database |
| Global Market Projection |
$1.2–1.5 billion by 2025 |
Market research reports |
| Patent Expiry |
2030+ |
Patent filings and legal databases |
Key Takeaways
- NDC 59212-0701 (Reblozyl) has established itself as a leading treatment in anemia-related hematologic conditions.
- Revenue growth remains strong but is approaching a plateau in mature markets.
- Pricing remains high, with limited competition, though biosimilar entry is likely by 2025.
- Market expansion depends on new indications and regulatory approvals.
- Future pricing will be influenced heavily by regulatory, reimbursement, and biosimilar developments.
FAQs
1. When will biosimilars for Reblozyl enter the market?
Likely post-2025, contingent on patent expirations and regulatory approvals.
2. How does the pricing compare internationally?
International prices vary significantly, often 20–30% lower than U.S. prices due to differing healthcare systems and negotiation power.
3. What is the potential for off-label use?
Off-label expansion is limited by clinical trials; any new approved indications could significantly impact revenues.
4. How does Reblozyl’s efficacy compare to competitors?
Clinical trials indicate comparable or superior efficacy in specific indications, supporting premium pricing.
5. Are there upcoming regulatory decisions that could impact the market?
Yes, approval of additional indications and biosimilar filings could influence overall market dynamics and pricing.
Sources:
- Bristol-Myers Squibb. (2022). Annual Earnings Reports.
- CDC. (2022). Hematologic Disease Prevalence Data.
- Industry reports from EvaluatePharma and IQVIA.
